


CONCLUSION

Applicants submit that the pending claims are in proper condition for allowance. Early notification to that effect is respectfully requested.

Attached hereto is a marked-up version of the changes made to the specification by the current amendment. The attached page is captioned "**Version with markings to show changes made.**"

Respectfully submitted,


Felicity E. Groth
Registration No. 47,042

Date: *November 20, 2002*
WOODCOCK WASHBURN LLP
One Liberty Place - 46th Floor
Philadelphia, PA 19103
(215) 568-3100

Attachments

Paper Copy of the Substitute Sequence Listing
Substitute Sequence Listing in Computer Readable Form
Statement to Support Filing and Submission of Substitute Sequence Listing
Version with Markings to Show Changes Made



VERSION WITH MARKING TO SHOW CHANGES MADE

Please enter the following amendments:

IN THE SPECIFICATION:

The MMR proficient mouse H36 hybridoma cell line was transfected with various *hPMS2* expression plasmids plus reporter constructs for assessing MMR activity. The MMR genes were cloned into the pEF expression vector, which contains the elongation factor promoter upstream of the cloning site followed by a mammalian polyadenylation signal. This vector also contains the NEO^r gene that allows for selection of cells retaining this plasmid. Briefly, cells were transfected with 1 µg of each vector using polyliposomes following the manufacturer's protocol (Life Technologies). Cells were then selected in 0.5 mg/ml of G418 for 10 days and G418 resistant cells were pooled together to analyze for gene expression. The pEF construct contains an intron that separates the exon 1 of the EF gene from exon 2, which is juxtaposed to the 5' end of the polylinker cloning site. This allows for a rapid reverse transcriptase polymerase chain reaction (RT-PCR) screen for cells expressing the spliced products. At day 17, 100,000 cells were isolated and their RNA extracted using the trizol method as previously described (Nicolaidis N.C., Kinzler, K.W., and Vogelstein, B. (1995) Analysis of the 5' region of PMS2 reveals heterogeneous transcripts and a novel overlapping gene. *Genomics* 29:329-334). RNAs were reverse transcribed using Superscript II (Life Technologies) and PCR amplified using a sense primer located in exon 1 of the EF gene (5'-ttt cgc aac ggg ttt gcc g-3') (SEQ ID NO: 17) and an antisense primer (5'-gtt tca gag tta agc ctt cg-3') (SEQ ID NO: 18) centered at nt 283 of the published human PMS2 cDNA, which will detect both the full length as well as the PMS134 gene expression. Reactions were carried out using buffers and conditions as previously described (Nicolaidis, N.C., *et al.* (1995) Genomic organization of the human PMS2 gene family. *Genomics* 30:195-206), using the following amplification parameters: 94°C for 30 sec, 52°C for 2 min, 72°C for 2 min, for 30 cycles. Reactions were analyzed on agarose gels. Figure 1 shows a representative example of PMS expression in stably transduced H36 cells.

RECEIVED

NOV 22 2002

TECH CENTER 1600, 2000

DOCKET NO.: MOR-0003

PATENT

6

IN THE SEQUENCE LISTING:

Please insert pages 1-26 of the Substitute Sequence Listing.



A DOCPHOENIX

APPL PARTS

____ IMIS ____

Internal Misc. Paper

____ LET. ____

Misc. Incoming Letter

____ 371P ____

PCT Papers in a 371 Application

____ A... ____

Amendment Including Elections

____ ABST ____

Abstract

____ ADS ____

Application Data Sheet

____ AF/D ____

Affidavit or Exhibit Received

____ APPENDIX ____

Appendix

____ ARTIFACT ____

Artifact

____ BIB ____

Bib Data Sheet

____ CLM ____

Claim

____ COMPUTER ____

Computer Program Listing

11-22-02 CRFL 2

All CRF Papers for Backfile

____ DIST ____

Terminal Disclaimer Filed

____ DRW ____

Drawings

____ FOR ____

Foreign Reference

____ FRPR ____

Foreign Priority Papers

____ IDS ____

IDS Including 1449

____ NPL ____

Non-Patent Literature

____ OATH ____

Oath or Declaration

____ PET. ____

Petition

____ RETMAIL ____

Mail Returned by USPS

____ SEQLIST ____

Sequence Listing

____ SPEC ____

Specification

____ SPEC NO ____

Specification Not in English

____ TRNA ____

Transmittal New Application

____ CTNF ____

Count Non-Final

____ CTRS ____

Count Restriction

____ EXIN ____

Examiner Interview

____ M903 ____

DO/EO Acceptance

____ M905 ____

DO/EO Missing Requirement

____ NFDR ____

Formal Drawing Required

____ NOA ____

Notice of Allowance

____ PETDEC ____

Petition Decision

OUTGOING

____ CTMS ____

Misc. Office Action

____ 1449 ____

Signed 1449

____ 892 ____

892

____ ABN ____

Abandonment

____ APDEC ____

Board of Appeals Decision

____ APEA ____

Examiner Answer

____ CTAV ____

Count Advisory Action

____ CTEQ ____

Count Ex parte Quayle

____ CTFR ____

Count Final Rejection

INCOMING

____ AP.B ____

Appeal Brief

____ C.AD ____

Change of Address

____ N/AP ____

Notice of Appeal

____ PA.. ____

Change in Power of Attorney

____ REM ____

Applicant Remarks in Amendment

____ XT/ ____

Extension of Time filed separate

BACKFILE DOCUMENT INDEX SHEET

Internal

____ SRNT ____

Examiner Search Notes

____ CLMPTO ____

PTO Prepared Complete Claim Set

____ ECBOX ____

Evidence Copy Box Identification

____ WCLM ____

Claim Worksheet

____ WFEE ____

Fee Worksheet

File Wrapper

____ FWCLM ____

File Wrapper Claim

____ IIFW ____

File Wrapper Issue Information

____ SRFW ____

File Wrapper Search Info